Karyopharm Therapeutics Inc.
KPTIOther · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $146.1M | $145.2M | $146.0M | $157.1M | $209.8M | $108.1M |
| Operating income | −$90.7M | −$119.4M | −$129.5M | −$142.2M | −$98.3M | −$171.8M |
| Net income | −$196.0M | −$76.4M | −$143.1M | −$165.3M | −$124.1M | −$196.3M |
| Total assets | $108.4M | $164.4M | $240.4M | $358.2M | $305.3M | $313.1M |
| Total liabilities | $401.3M | $350.4M | $376.6M | $374.8M | $385.0M | $262.5M |
| Equity | −$292.9M | −$186.0M | −$136.2M | −$16.7M | −$79.7M | $50.5M |
| EPS (diluted) | $-17.93 | $-14.00 | $-18.79 | $-2.02 | $-1.65 | $-2.72 |
| Shares out. | 126.2M | 115.1M | 113.3M | 79.2M | 74.6M | 65.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −62.1%
- Net margin
- −134.2%
- Return on equity
- 66.9%
- Return on assets
- −180.8%
- Return on capital (ROCE)
- −554.6%
- Liabilities / assets
- 370.2%
- Debt / equity
- —
- Book value / share
- $-2.32
- Revenue growth (YoY)
- 0.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -58.62distress
- Accruals / assets
- −111.3%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Oliger Christy J.Director | May 21, 2026 | Grant | 15,508 | $0.00 |
| Pakianathan DeepikaDirector | May 21, 2026 | Grant | 15,508 | $0.00 |
| Schor ChenDirector | May 21, 2026 | Grant | 15,508 | $0.00 |
| Su ZhenDirector | May 21, 2026 | Grant | 15,508 | $0.00 |
| Bohlin Garen GDirector | May 21, 2026 | Grant | 15,508 | $0.00 |
| Greene Barry EDirector | May 21, 2026 | Grant | 15,508 | $0.00 |
| Poulton StuartOfficer — EVP, Chief Development Officer | May 13, 2026 | Grant | 896 | $0.00 |
| Rangwala ReshmaOfficer — EVP & Chief Medical Officer | May 13, 2026 | Grant | 947 | $0.00 |
| Cheng Sohanya RoshanOfficer — EVP & Chief Commercial Officer | May 13, 2026 | Grant | 947 | $0.00 |
| Abate KristinOfficer — Chief Accounting Officer | May 13, 2026 | Grant | 121 | $0.00 |
| Paulson Richard A.Officer — President and CEO | May 13, 2026 | Grant | 4,920 | $0.00 |
| Mano MichaelOfficer — EVP, CLO&Secretary | May 13, 2026 | Grant | 700 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 5.3M | 11.5 | -0.3% |
| Apr 30, 2026 | 5.3M | 14.5 | -7.4% |
| Apr 15, 2026 | 5.7M | 9.0 | +4.8% |
| Mar 31, 2026 | 5.5M | 2.3 | +51.9% |
| Mar 13, 2026 | 3.6M | 5.0 | +20.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteMay 28, 2026
- Results of operationsMay 14, 2026
- Other material eventMar 27, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosure · Other material eventMar 24, 2026
- Entered a material agreement · Other material eventMar 3, 2026
- Shareholder voteFeb 19, 2026
- Results of operationsFeb 12, 2026
- Results of operations · Other material eventJan 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.